Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0RJ2V
|
|||
| Drug Name |
LMP1-CAR-T cells
|
|||
| Drug Type |
CAR T Cell Therapy
|
|||
| Indication | Nasopharyngeal carcinoma [ICD-11: 2B6B] | Phase 1/2 | [1] | |
| Company |
The Second Hospital of Nanjing Medical University
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Epstein-Barr virus Latent membrane protein 1 (EBV LMP1) | Target Info | CAR-T-Cell-Therapy | [1] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02980315) A New EBV Related Technologies of T Cells in Treating Malignant Tumors and Clinical Application | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.